Supercharged immune cells aim to stop lymphoma comeback
NCT ID NCT02663297
First seen Jun 11, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The main goal is to find a safe dose and see if these engineered cells can prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27157, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATLCAR.CD30 cells (engineered T cells that target CD30 on lymphoma cells)
What this could lead to
If successful, this approach could help prevent lymphoma from returning after a stem cell transplant, offering a new way to keep the cancer in check.
What could go wrong
This is an early phase 1 trial with only 18 participants, so it is primarily testing safety and dosing. The treatment may not work as hoped, and side effects like cytokine release syndrome are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.